Fresenius Medical Care AG reported robust third-quarter results, with net income increasing 29% to 275 million euros and adjusted operating income rising 22% to 574 million euros, driven by an 8% constant currency revenue growth to 4.89 billion euros. The company reaffirmed its fiscal 2025 outlook, anticipating positive to low-single digit constant currency revenue growth and high-teens to high-twenties percent growth in adjusted operating income.
Fresenius Medical Care AG (FMS) reported a robust third quarter, with net income attributable to shareholders increasing 29% to €275 million and adjusted net income growing 36% to €322 million. Basic EPS rose 30% to €0.94, while adjusted basic EPS increased 36% to €1.10. This strong profitability was supported by group revenue growth of 3% to €4.89 billion, accelerating to 8% at constant currency and 10% organically across all operating segments. Operating income saw a 3% increase to €477 million, with adjusted operating income showing a more significant 22% rise to €574 million, indicating improved operational efficiency. The company maintained its fiscal 2025 outlook, projecting positive to low-single digit constant currency revenue growth and high-teens to high-twenties percent growth in operating income excluding special items. This consistent guidance, despite strong Q3 results, suggests management confidence in sustained performance. The reaffirmation of the 2025 outlook, alongside the strong Q3 performance, underscores the company's fundamental strength and execution. The FME25+ savings program, targeting €1.05 billion in savings by year-end 2027 against program costs of €1.0 billion to €1.05 billion, indicates a strategic focus on long-term efficiency and profitability. These initiatives are expected to contribute to future earnings growth, reinforcing the positive sentiment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
